Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wegovy Starting Doses Restrictions Will Continue Through The Year

Executive Summary

Supply of the obesity drug has outpaced demand in the US, and Novo Nordisk said that will persist throughout 2023.

You may also be interested in...

Amgen’s Plan To Go Big In Obesity

Competing in the obesity market will require significant investment, which Amgen is preparing for, CEO Robert Bradway told investors during the Morgan Stanley Healthcare conference.

Novo Nordisk STEPs Into Heart Failure

The company’s metabolic juggernaut looks like a winner in obesity plus HFpEF, but making comparisons with approved products is tricky – and meeting demand is trickier still.

Obesity Drug Coverage In Employer-Sponsored Plans On Slow Build Trajectory, Survey Finds

Large employer plan sponsors split on whether to cover GLP-1 drugs for weight loss, according to a recent survey.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts